Claims for Patent: 9,512,079

Summary for Patent: 9,512,079

Title:	Deuterated CFTR potentiators
Abstract:	This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
Inventor(s):	Adam J. Morgan
Assignee:	Vertex Pharmaceuticals Europe Ltd, Sun Pharmaceutical Industries Inc
Application Number:	US14/921,158
Patent Claims:	1. A compound represented by the formula: or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance, and wherein the deuterium incorporation at each designated deuterium atom is at least 90%. 2. The compound of claim 1, wherein the compound is Compound 106, or a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 4. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 3. 5. A method of treating COPD in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 3. 6. The compound of claim 1, wherein the compound is Compound 105, or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1, wherein the deuterium incorporation at each designated deuterium atom is at least 95%. 8. The compound of claim 1, wherein the deuterium incorporation at each designated deuterium atom is at least 97%. 9. The compound of claim 2, wherein the deuterium incorporation at each designated deuterium atom is at least 95%. 10. The compound of claim 2, wherein the deuterium incorporation at each designated deuterium atom is at least 97%. 11. The compound of claim 6, wherein the deuterium incorporation at each designated deuterium atom is at least 95%. 12. The compound of claim 6, wherein the deuterium incorporation at each designated deuterium atom is at least 97%. 13. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 2. 14. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 9. 15. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 10.